164 related articles for article (PubMed ID: 38376848)
1. Glioblastoma patients' survival and its relevant risk factors during the pre-COVID-19 and post-COVID-19 pandemic: real-world cohort study in the USA and China.
Qin L; Li H; Zheng D; Lin S; Ren X
Int J Surg; 2024 May; 110(5):2939-2949. PubMed ID: 38376848
[TBL] [Abstract][Full Text] [Related]
2. Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis.
Wen J; Chen W; Zhu Y; Zhang P
BMC Cancer; 2021 Jan; 21(1):81. PubMed ID: 33468109
[TBL] [Abstract][Full Text] [Related]
3. Improved survival time trends for glioblastoma using the SEER 17 population-based registries.
Koshy M; Villano JL; Dolecek TA; Howard A; Mahmood U; Chmura SJ; Weichselbaum RR; McCarthy BJ
J Neurooncol; 2012 Mar; 107(1):207-12. PubMed ID: 21984115
[TBL] [Abstract][Full Text] [Related]
4. Patient and treatment factors associated with survival among adult glioblastoma patients: A USA population-based study from 2000-2010.
Pan IW; Ferguson SD; Lam S
J Clin Neurosci; 2015 Oct; 22(10):1575-81. PubMed ID: 26122381
[TBL] [Abstract][Full Text] [Related]
5. Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study.
Zhu P; Du XL; Lu G; Zhu JJ
Oncotarget; 2017 Jul; 8(27):44015-44031. PubMed ID: 28467795
[TBL] [Abstract][Full Text] [Related]
6. Ambient carbon monoxide exposure and elevated risk of mortality in the glioblastoma patients: A double-cohort retrospective observational study.
Yoon SJ; Noh J; Son HY; Moon JH; Kim EH; Park SW; Kim SH; Chang JH; Huh YM; Kang SG
Cancer Med; 2020 Dec; 9(23):9018-9026. PubMed ID: 33161654
[TBL] [Abstract][Full Text] [Related]
7. Competing risk model to determine the prognostic factors and treatment strategies for elderly patients with glioblastoma.
Liu ZY; Feng SS; Zhang YH; Zhang LY; Xu SC; Li J; Cao H; Huang J; Fan F; Cheng L; Jiang JY; Cheng Q; Liu ZX
Sci Rep; 2021 Apr; 11(1):9321. PubMed ID: 33927308
[TBL] [Abstract][Full Text] [Related]
8. Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosis.
Kozak KR; Moody JS
Neuro Oncol; 2009 Dec; 11(6):833-41. PubMed ID: 19332771
[TBL] [Abstract][Full Text] [Related]
9. A survival analysis of GBM patients in the West of Scotland pre- and post-introduction of the Stupp regime.
Teo M; Martin S; Owusu-Agyemang K; Nowicki S; Clark B; Mackinnon M; Stewart W; Paul J; St George J
Br J Neurosurg; 2014 Jun; 28(3):351-5. PubMed ID: 24111708
[TBL] [Abstract][Full Text] [Related]
10. Treatment and survival of patients harboring histological variants of glioblastoma.
Ortega A; Nuño M; Walia S; Mukherjee D; Black KL; Patil CG
J Clin Neurosci; 2014 Oct; 21(10):1709-13. PubMed ID: 24980627
[TBL] [Abstract][Full Text] [Related]
11. Glioblastomas with oligodendroglial component have the same clinical phenotype as classical glioblastomas.
Elmahdi A; Frary AJ; Scotton WJ; O'Donovan DG; Price SJ
Br J Neurosurg; 2013 Aug; 27(4):419-24. PubMed ID: 23418780
[TBL] [Abstract][Full Text] [Related]
12. Patient and treatment factors associated with survival among pediatric glioblastoma patients: A Surveillance, Epidemiology, and End Results study.
Lam S; Lin Y; Zinn P; Su J; Pan IW
J Clin Neurosci; 2018 Jan; 47():285-293. PubMed ID: 29102237
[TBL] [Abstract][Full Text] [Related]
13. Influence of insurance status on survival of adults with glioblastoma multiforme: A population-based study.
Rong X; Yang W; Garzon-Muvdi T; Caplan JM; Hui X; Lim M; Huang J
Cancer; 2016 Oct; 122(20):3157-3165. PubMed ID: 27500668
[TBL] [Abstract][Full Text] [Related]
14. Impact of gender on the survival of patients with glioblastoma.
Tian M; Ma W; Chen Y; Yu Y; Zhu D; Shi J; Zhang Y
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30305382
[No Abstract] [Full Text] [Related]
15. Effect of marital status on survival in glioblastoma multiforme by demographics, education, economic factors, and insurance status.
Xie JC; Yang S; Liu XY; Zhao YX
Cancer Med; 2018 Aug; 7(8):3722-3742. PubMed ID: 30009575
[TBL] [Abstract][Full Text] [Related]
16. Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis.
Thumma SR; Fairbanks RK; Lamoreaux WT; Mackay AR; Demakas JJ; Cooke BS; Elaimy AL; Hanson PW; Lee CM
World J Surg Oncol; 2012 May; 10():75. PubMed ID: 22553975
[TBL] [Abstract][Full Text] [Related]
17. The validity of EORTC GBM prognostic calculator on survival of GBM patients in the West of Scotland.
Teo M; Clark B; MacKinnon M; Stewart W; Paul J; St George J
Br J Neurosurg; 2014 Jun; 28(3):356-62. PubMed ID: 24111707
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Time Series Forecasting and Updates on Survival Analysis of Glioblastoma Multiforme: A 1975-2018 Population-Based Study.
Alexopoulos G; Zhang J; Karampelas I; Patel M; Kemp J; Coppens J; Mattei TA; Mercier P
Neuroepidemiology; 2022; 56(2):75-89. PubMed ID: 35172317
[TBL] [Abstract][Full Text] [Related]
19. Association between giant cell glioblastoma and glioblastoma multiforme in the United States: A retrospective cohort study.
Bin Abdulrahman AK; Bin Abdulrahman KA; Bukhari YR; Faqihi AM; Ruiz JG
Brain Behav; 2019 Oct; 9(10):e01402. PubMed ID: 31464386
[TBL] [Abstract][Full Text] [Related]
20. Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries.
Darefsky AS; King JT; Dubrow R
Cancer; 2012 Apr; 118(8):2163-72. PubMed ID: 21882183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
